AT-56|cas 162640-98-4|DC Chemicals

Cas No.:	162640-98-4
Chemical Name:	AT 56
Synonyms:	AT 56;4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-[4-(2H-tetrazol-5-yl)butyl]-piperidine;AT-56;4-(DIBENZO[1,2-A:1',2'-E][7]ANNULEN-11-YLIDENE)-1-[4-(2H-TETRAZOL-5-YL)BUTYL]PIPERIDINE;4-Dibenzo[a,d]cyclohepten-5-ylidene-1-[4-(2H-tetrazol-5-yl)-butyl]-piperidine;4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-[4-(1H-tetrazol-5-yl)butyl]piperidine
SMILES:	C1=CC=C2C(=C1)C=CC3=CC=CC=C3C2=C4CCN(CCCCC5=NNN=N5)CC4
Formula:	C₂₅H₂₇N₅
M.Wt:	397.51538
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	AT-56 is a potent, selective and orally active inhibitor of lipocalin-type prostaglandin D synthase (L-PGDS), with an IC50 of 95 μM and Ki of 75 μM. AT-56 could selectively suppress the drowsiness or pain reaction mediated by L-PGDS-catalyzed PGD2[1].
In Vivo:	AT-56 ( 1-30 mg/kg; p.o.) suppresses the PGD2 production in the stab-wounded brain[1]. AT-56 (1-10 mg/kg; p.o.) suppresses the L-PGDS-mediated allergic airway inflammation in mice[1]. AT-56 (10 mg/kg; p.o.) exhibits Cmax (2.15 μg/ml), half-life (1.71 h) and high oral bioavailability (82%)[1]. Animal Model: H-PGDS KO mice (14-16weeks, 25-30 g, C57BL/6 strain) with a stab wound brain injury[1] Dosage: 0, 1, 3, 10, 30 mg/kg Administration: P.o. 1 h before the stab wound injury Result: Inhibited the L-PGDS reaction in the brain. Decreased the total amount of PGD2 in the brain to 40% with 30 mg/kg AT-56. Animal Model: Human L-PGDS-overexpressing TG mice (males, 14-16 weeks, 25-30 g)[1] Dosage: 0, 1, 10 mg/kg Administration: P.o. 1 h before and 24 h after the antigen exposure Result: Prevented the eosinophil infiltration by inhibiting transgened human L-PGDS. Animal Model: Male C57BL/6 mice (7 weeks, 22-26 g)[1] Dosage: 10 mg/kg for p.o. and 2 mg/kg for i.v. (Pharmacokinetic Analysis) Administration: P.o. and i.v. administration Result: Oral bioavailability (82%); Cmax (2.15 μg/ml); T1/2 (1.71 h, p.o.); T1/2 (2.35 h, i.v.).
In Vitro:	AT-56 (1-30 μM; 10 minutes) dose-dependently inhibits the production of PGD2 in L-PGDS-expressing human medulloblastoma TE-671 cells with an IC50 of about 3 μM[1].

Cat. No.	Product name	Field of application
DC48172	BAY-6672	BAY-6672 is a potent and selective human Prostaglandin F (FP) receptor antagonist with an IC50 value of 11 nM.
DC10475	Grapiprant	Grapiprant is a selective EP4 receptor antagonist whose physiological ligand is prostaglandin E2 (PGE2)
DC8348	TG6-10-1	TG6-10-1 is a cell-permeable,highly potent, selective, and competitive antagonist of prostaglandin E2 receptor (EP2, Kb = 17.8 nM).
DC9609	Terutroban	Terutroban is a thromboxane/prostaglandin endoperoxide receptor antagonist.
DC8624	Setipiprant(ACT129968)	Setipiprant is an orally available, selective CRTH2 antagonist. CRTH2 is a G protein-coupled receptor for PGD2.
DC8353	PF-04418948	PF-04418948 is an orally active, potent, and selective EP2 receptor antagonist (IC50 = 16 nM).
DC11043	Omidenepag	Omidenepag is a potent, selective agonist human EP2 receptor with binding IC50/EC50 of 10/1.7 nM, >500-fold selectivity over EP1, EP3 and EP4 receptors; Omidenepag is the active form of Omidenepag Isopropyl (OMDI).
DC10437	MRE-269	MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist.
DC10785	MK-7246	MK-7246 is a potent and selective CRTH2 antagonist with a Ki of 2.5±0.5 nM.
DC1009	Laropiprant	MK 0524 is a potent, selective DP1 receptor antagonist with Ki values of 0.57 nM and 0.75 µM for the DP1 and DP2 receptors, respectively.